Save over 93% with generic version of Palbace and 80% with brand from Pfizer today at insulinhub. Palbace is also known internationally as Primcyv, and Reampla made by Pfizer.
Click here for information on Cipla generics (Immediate availability)
Palbace, Reampla and Primcyv from Pfizer are manufactured at: either their factory in Germany or the USA:
M/s. Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg; Mooswaldallee 1 Freiburg - 79090 NA (Germany). or their factory in the United States
Information about Palbace (Palbociclib)
Palbace (generic name Palbociclib) is a targeted therapy medication used primarily in the treatment of certain types of cancer. It belongs to a class of drugs known as CDK4/6 inhibitors, which work by interfering with the cancer cells' ability to divide and grow.
Product Highlights
- Specifically in combination with an aromatase inhibitor or letrozole as first-line treatment in postmenopausal women, or in combination with letrozole for premenopausal women with HR-positive, HER2-negative breast cancer.
- HR-positive, HER2-negative breast cancer in combination with letrozole or fulvestrant for patients who have had disease progression after endocrine therapy.
- It is used in combination therapy, not as a monotherapy.
Key Ingredient
Key Benefits
- Palbociclib has demonstrated clinical efficacy in combination with other endocrine therapies for HR-positive, HER2-negative breast cancer.
- Studies have shown that Palbociclib, in combination with aromatase inhibitors or other therapies, can significantly extend progression-free survival in patients.
- The drug is taken orally, providing a more convenient method of treatment compared to intravenous chemotherapy.
- Palbociclib has been extensively studied in clinical trials, showing significant efficacy and safety in treating specific types of breast cancer.
Direction of Use
- Palbociclib is usually taken once daily for 21 days followed by a 7-day break, in a 28-day cycle. The recommended starting dose is 125 mg once daily for most patients.
- The tablets should be swallowed whole, with or without food.
- Often used in combination with other breast cancer medications like letrozole (an aromatase inhibitor) or fulvestrant (an estrogen receptor antagonist).
- During treatment, patients should have regular blood tests to monitor for side effects such as low white blood cell count.
Safety Concerns
- Palbociclib can cause a significant reduction in white blood cells (neutropenia), increasing the risk of infection. Regular blood tests are required.
- Diarrhea, nausea, and vomiting are common side effects.
- Many patients report feeling tired or fatigued during treatment.
- Liver function tests should be monitored, as Palbociclib can affect liver enzymes.
- Due to the suppression of white blood cells, there is a higher risk of infection, including respiratory and urinary tract infections.
- Palbociclib may affect the heart's electrical rhythm, so caution should be used in patients with existing heart conditions.
Avoid Palbace (Palbociclib) If
- If the patient has a low white blood cell count (neutropenia) or severe bone marrow suppression, Palbociclib should be avoided or discontinued.
- Palbociclib is not recommended during pregnancy as it can cause harm to a developing fetus. Women of reproductive age should use reliable contraception while undergoing treatment.
- Patients with severe liver problems should not take Palbociclib, as it is metabolized in the liver and may worsen liver dysfunction.
- If the patient has a known allergy to Palbociclib or any of its components, the drug should be avoided.
- Palbociclib is not recommended for use during breastfeeding, as it may pass into breast milk and harm the nursing infant.
